ArticleBMC cardiovascular disorders2026
Blunted heart rate response during dipyridamole stress SPECT is associated with cardiovascular outcomes in an all-comers cohort.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDipyridamole stress cardiac 99mTc-SPECT (DS-SPECT) is commonly used to detect myocardial ischemia. Blunted heart rate response (BHRR) during pharmacologic stress has been associated with adverse outcomes. This study evaluated the significance of BHRR in an unselected real-world DS-SPECT cohort and compared it with routine imaging findings.
methodsIn this single-center retrospective cohort study, all adult patients who underwent dipyridamole stress SPECT without adjunct exercise between 2014 and 2017 were included. Clinical data were obtained from the electronic medical record and structured pre-test interviews, and patients were followed through September 2020.
resultsStudy population consisted of 388 patients, 227 (58.5%) had normal imaging results, and 245 (63.1%) exhibited BHRR. During a mean follow-up of four years, multivariable analysis found association of BHRR with cardiovascular death (HR 8.09, 95% CI:1.06-61.91, p < 0.05). Patients with abnormal DS-SPECT imaging and BHRR had a nearly fourfold increased risk of adverse cardiovascular events (HR 3.79, 95% CI: 1.24-11.63, p < 0.05). Moreover, individuals demonstrating both abnormal imaging results and BHRR experienced the highest rate of all-cause mortality (HR 2.93, 95% CI: 1.1-7.7, p < 0.01). Overall, BHRR significantly correlated with increased all-cause and cardiovascular mortality.
conclusionsIn unselected patients referred to DS-SPECT, BHRR was associated with cardiovascular mortality. Moreover, in our population group, when combined with abnormal imaging results, BHRR significantly increases the association with DS-SPECT for cardiovascular morbidity and all-cause mortality. These findings may support future inclusion of BHRR in DS-SPECT studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.